RxDoctor Payments Data

Shaila Gupta, DO

Neurology · Munster, INNPI 1902095938

Payments from drug & device makers

$17,345in general payments, 2019–2025

Across 1,013 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biogen$2K
  • SK Life Science, Inc.$1K
  • Lundbeck LLC$875
  • UCB, Inc.$843
  • Novartis$673
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$1731%
  • Food & beverage$17,17299%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)157$2,618
Biogen82$1,577
SK Life Science, Inc.63$1,071
Lundbeck LLC45$875
UCB, Inc.70$843
Novartis51$673
Teva Pharmaceuticals USA, Inc.41$540
Pfizer39$533
Amneal Pharmaceuticals LLC31$523
Acadia Pharmaceuticals Inc31$507
Amgen31$501
AstraZeneca(2 entities)23$436
Lilly USA, LLC28$425
Neurocrine Biosciences, Inc.19$395
Neurelis, Inc.13$351
Avadel CNS Pharmaceuticals, LLC15$335
Biohaven Pharmaceutical Holding Company Ltd.20$310
Jazz Pharmaceuticals Inc.11$307
Sanofi15$294
Acorda Therapeutics, Inc19$293
Banner Life Sciences, LLC13$254
Supernus Pharmaceuticals, Inc.14$245
MDD US Operations, LLC14$242
Johnson & Johnson11$209
Vanda Pharmaceuticals Inc.7$204
Corium, LLC9$200
Biohaven Pharmaceuticals, Inc.16$193
Argenx US, Inc.9$184
Genentech USA, Inc.8$152
Greenwich Biosciences, Inc.6$140
W. L. Gore & Associates, Inc.1$138
EMD Serono, Inc.9$126
Aucta Pharmaceuticals, Inc.5$103
Azurity Pharmaceuticals, Inc.6$100
Arbor Pharmaceuticals, Inc.8$99
Sunovion Pharmaceuticals Inc.4$92
Eisai Inc.5$89
Upsher-smith Laboratories LLC6$87
Vertical Pharmaceuticals, LLC2$81
Bristol Myers Squibb4$73
Axsome Therapeutics, Inc.3$64
Adamas Pharmaceuticals, Inc.4$60
Cycle Pharmaceuticals Inc3$57
TG Therapeutics, Inc.3$55
Otsuka America Pharmaceutical, Inc.3$54
Catalyst Pharmaceuticals, Inc.2$52
Ceribell, Inc.1$50
Impel Pharmaceuticals Inc.3$50
CSL Behring3$47
Tanabe Pharma America, Inc.3$46
E.r. Squibb & Sons, L.L.C.2$35
Scilex Pharmaceuticals Inc.2$33
Currax Pharmaceuticals LLC2$28
Mallinckrodt Hospital Products Inc.2$27
Assertio Therapeutics, Inc.2$27
Octapharma USA, Inc.1$24
Kyowa Kirin, Inc.1$23
Livanova USA, Inc.1$20
Takeda Pharmaceuticals U.S.A., Inc.1$19
Avanir Pharmaceuticals, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,345 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$227,951
Medicare patients
1,052
Services billed
2,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5025$421,214
Avonex Pen (4 Pack)Interferon Beta-1a15$122,797
Kesimpta PenOfatumumab12$121,729
VumerityDiroximel Fumarate12$105,781
CopaxoneGlatiramer Acetate18$102,141
AubagioTeriflunomide11$98,071
NuplazidPimavanserin Tartrate12$96,426
EpidiolexCannabidiol (Cbd)12$72,433
Aimovig AutoinjectorErenumab-Aooe51$59,502
VimpatLacosamide39$59,142
BriviactBrivaracetam30$56,413
QuliptaAtogepant46$56,332
KeppraLevetiracetam16$39,526
SympazanClobazam11$34,432
NeuproRotigotine26$33,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$19$421,21425 claims
UCB, Inc.Vimpat, Briviact, Neupro$843$149,44495 claims
BiogenVumerity$1,577$105,78112 claims
Teva Pharmaceuticals USA, Inc.Copaxone$540$102,14118 claims
SanofiAubagio$294$98,07111 claims
Acadia Pharmaceuticals IncNuplazid$507$96,42612 claims
AbbVieQulipta, Namzaric, Linzess$2,618$90,72792 claims
PfizerNurtec Odt$533$24,10722 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$245$14,65811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 308 neurology providers in Indiana.

Other neurology in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →